Zymeworks Inc ZYME.OQ ZYME.O is expected to show a fall in quarterly revenue when it reports results on March 2 for the period ending December 31 2025
The Middletown Delaware-based company is expected to report a 56.2% decrease in revenue to $13.576 million from $31.03 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Zymeworks Inc is for a loss of 42 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Zymeworks Inc is $34.00, about 42.8% above its last closing price of $23.81
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.29 | -0.32 | -0.26 | Beat | 19 |
Jun. 30 2025 | -0.48 | -0.49 | 0.03 | Beat | 106.1 |
Mar. 31 2025 | -0.40 | -0.41 | -0.30 | Beat | 26.6 |
Dec. 31 2024 | -0.17 | -0.10 | -0.31 | Missed | -213.1 |
Sep. 30 2024 | -0.31 | -0.40 | -0.39 | Beat | 1.4 |
Jun. 30 2024 | -0.33 | -0.32 | -0.27 | Beat | 14.7 |
Mar. 31 2024 | -0.29 | -0.29 | -0.42 | Missed | -44.8 |
Dec. 31 2023 | -0.46 | -0.43 | -0.20 | Beat | 53.9 |
This summary was machine generated February 27 at 13:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)